Aptose Biosciences Stock News

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the U.S.

In this article you are going to find out whether hedge funds think Aptose Biosciences Inc (NASDAQ:APTO) is a good investment right now. We like to check what the smart money thinks first before doing

Bull or bear market, no investment is a sure thing. Especially in the current financial environment, which remains riddled with uncertainty, finding compelling plays can be challenging for even the mo

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of canc

SAN DIEGO and TORONTO, June 02, 2020 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28) ADC Therapeutics SA (NYSE:...

SAN DIEGO and TORONTO, May 14, 2020 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated.

We can readily understand why investors are attracted to unprofitable companies. For example, Aptose Biosciences...

SAN DIEGO and TORONTO, May 07, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.

APTO earnings call for the period ending March 31, 2020.